Phase 2 Study Comparing Cancer Treatment at Home Versus in Clinic for Black Men with Advanced or Metastatic Prostate Cancer

What this Trial Is About

Researchers are evaluating cancer treatment given at home versus in a clinic for Black men with locally advanced, biochemically recurrent, or metastatic prostate cancer. This phase II trial aims to compare safety, side effects, patient preference, and satisfaction between these two care settings. The study recognizes that receiving treatment in a familiar home environment may reduce physical, emotional, social, and financial burdens for patients and their families. Participants initially receive standard cancer treatments in a clinic for 6 to 12 weeks. If there is no disease progression or unacceptable toxicity, treatment continues at home for 12 to 24 weeks using the Cancer Connected Access and Remote Expertise Beyond Walls CCBW system, which includes home health providers and remote monitoring support. Any remaining treatments are then completed in the clinic. Treatments include intravenous or subcutaneous drugs such as hormone therapies, chemotherapy, immunotherapy, and bone modifying agents. During the study, participants will complete questionnaires about their care experience and preferences. Researchers will monitor safety by tracking serious side effects, emergency visits, hospitalizations, and avoidable acute care events. They will also assess patient-reported symptoms, quality of life, and satisfaction. The study lasts up to 48 weeks, with ongoing evaluations to understand treatment impact and costs in both home and clinic settings.

Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer